Who Owns KalVista Company?

KalVista Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns KalVista Pharmaceuticals?

Delving into the KalVista SWOT Analysis is just the beginning. Understanding the structure of is paramount for any investor or strategist. With a potential FDA approval for sebetralstat on the horizon, the stakes are higher than ever. This analysis unveils the key players shaping KalVista's future.

Knowing and their influence provides crucial insights into the company's strategic direction and potential for growth. This examination of will reveal the evolution of its shareholder base, including institutional investors and any significant shifts over time. Understanding the dynamics and the individuals behind the scenes is essential for informed decision-making in the biotechnology sector. This information could be used to understand the and the .

KalVista Pharmaceuticals, or simply KalVista, was established in 2011. The company's roots are in both Cambridge, Massachusetts, and Southampton, United Kingdom. Its inception involved a team of experienced researchers and industry professionals. They united to tackle unmet medical needs, specifically conditions like diabetic macular edema (DME).

Robert Haigh is identified as one of the founders of KalVista in 2011. The company's initial funding came from venture capital rounds and subsequent public offerings. These financial injections supported the early research and development activities of KalVista Pharmaceuticals. The company went public in 2015, trading on NASDAQ, which provided crucial capital to advance its clinical programs.

Specific details regarding the founding team's equity splits or initial shareholding are not readily available in public sources. Information on early backers, angel investors, or any initial ownership disputes is also not extensively detailed. However, the founding team's vision to develop innovative treatments for ophthalmic diseases and later hereditary angioedema was reflected in the strategic pursuit of novel small molecule plasma kallikrein inhibitors.

Key Aspects of KalVista's Early Days

The early stages of KalVista involved securing capital through venture capital and public offerings. This funding was essential for the company's research and development endeavors. The company's focus was on developing treatments for conditions like DME and later, hereditary angioedema. The company's initial public offering (IPO) in 2015 provided a significant financial boost.

• The company's headquarters is located in Portsmouth, New Hampshire.
• The company's stock is traded on the NASDAQ under the ticker symbol KALV.
• The company's focus is on developing treatments for diseases with significant unmet needs.
• The company's pipeline includes treatments for hereditary angioedema (HAE) and other indications.

KalVista SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The journey of KalVista Pharmaceuticals in the public market began on April 9, 2015, when it went public on NASDAQ. Since its initial public offering (IPO), the company has experienced significant growth. As of June 12, 2025, the market capitalization of KalVista reached $650.78 million, a substantial increase from its initial $129.30 million. This growth represents a compound annual growth rate of 17.20%, highlighting the company's progress and investor confidence.

The ownership structure of KalVista is heavily influenced by institutional investors. As of May 2025, institutional investors held approximately 102.54% of the shares, with mutual funds accounting for about 30.18%. Insiders increased their holdings from 2.72% to 2.90% during the same period. The presence of 260 institutional owners and shareholders, who have filed 13D/G or 13F forms with the SEC, holding a total of 61,630,628 shares as of June 12, 2025, further illustrates the significant role of institutional investors in the company's ownership.

The shifts in major shareholding reflect the dynamic nature of the investment landscape for clinical-stage biotech companies like KalVista Pharmaceuticals. These companies often require substantial capital to advance drug candidates through clinical trials and regulatory approvals. The significant institutional ownership indicates a strong belief in KalVista's pipeline, particularly sebetralstat, and its potential impact on the market. To understand the broader competitive environment, one can explore the Competitors Landscape of KalVista.

Key Takeaways on KalVista Ownership

KalVista has seen substantial growth since its IPO, with a market cap of $650.78 million as of June 12, 2025.

• Institutional investors hold a significant majority of KalVista shares.
• VR Adviser, LLC and Tang Capital Management LLC are among the major institutional stakeholders.
• The ownership structure reflects the need for capital in biotech for drug development.
• KalVista stock is influenced by institutional investor confidence.

KalVista PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of June 8, 2025, the leadership team at KalVista Pharmaceuticals includes Benjamin L. Palleiko as Chief Executive Officer and Director. The Board of Directors comprises Benjamin Palleiko, Edward Unkart, Brian J. Pereira (Independent Chairman), Laurence Reid, Nancy Stuart, William Fairey, and Patrick Treanor. Tomas Kiselak serves as a Board Observer. The average tenure of the board is 3.7 years, indicating a relatively experienced group guiding the company. The Brief History of KalVista provides additional context on the company's evolution.

The current leadership team also includes Christopher Yea as Chief Development Officer, Paul Audhya as Chief Medical Officer, Brian Piekos as Chief Financial Officer, and other key executives. Benjamin L. Palleiko, as CEO and Director, directly owns 0.62% of the company's shares, valued at $4.40 million. Dr. Paul K. Audhya, Chief Medical Officer, holds 0.63% of the shares (113,026 shares) as of May 22, 2025. Christopher M. Yea, Chief Development Officer, holds 0.55% of the shares (98,189 shares) as of May 22, 2025. This ownership structure provides insight into the alignment of interests between the leadership and KalVista Pharmaceuticals investors.

The voting structure at KalVista Pharmaceuticals typically follows a one-share-one-vote system, common among NASDAQ-listed public companies. The influence of major institutional shareholders, as detailed in the 'Ownership Evolution and Major Stakeholders' section, translates into significant voting power. There's no public information suggesting dual-class shares or special voting rights that would give disproportionate control to specific individuals. Recent SEC filings have not indicated any proxy battles or governance controversies that have significantly changed the company's decision-making processes. Understanding the KalVista ownership structure is crucial for anyone looking into KalVista stock or considering becoming KalVista investors.

Key Takeaways on KalVista Ownership and Governance

The Board of Directors at KalVista Pharmaceuticals is composed of experienced individuals, with an average tenure of 3.7 years.

• The CEO, Benjamin Palleiko, holds a notable percentage of the company's shares, aligning his interests with those of the shareholders.
• Key executives also have a stake in the company, further aligning interests.
• The voting structure is straightforward, with a one-share-one-vote system.
• No significant governance issues have been reported recently.

KalVista Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, several key developments have reshaped the ownership landscape of KalVista Pharmaceuticals. In November 2024, KalVista successfully raised approximately $160 million through a combination of synthetic royalty financing and equity offerings. This included a significant upfront payment from DRI Healthcare Trust and proceeds from a public offering. These financial maneuvers significantly bolstered the company's cash reserves, which stood at roughly $253.2 million as of January 31, 2025.

Leadership changes also played a role in the evolution of KalVista's ownership. Benjamin L. Palleiko was promoted to Chief Executive Officer and appointed to the Board of Directors in March 2024. Further, in May 2025, the company issued inducement stock options to new employees as part of a broader equity incentive program, aimed at attracting and retaining talent. These actions reflect the ongoing efforts to manage and influence the company's ownership structure.

Looking forward, the potential for sebetralstat's FDA approval, anticipated around June 17, 2025, represents a major catalyst for KalVista stock. Analysts have a positive outlook, with an average target price of $26.44, suggesting a potential upside. This could further attract investment and influence the company's ownership dynamics. The company's strategic review of its preclinical Factor XIIa inhibitor program also signals potential future development and ownership opportunities.

Financial Boost

A $160 million capital raise in November 2024 provided KalVista with substantial financial resources. This included a synthetic royalty financing agreement and equity offerings. The capital infusion strengthened the company's cash position, crucial for ongoing operations and development.

Leadership and Talent

Benjamin L. Palleiko's promotion to CEO in March 2024 marked a significant leadership change. The company's equity incentive program, which included stock options for new hires, aimed to attract and retain talent. These moves are part of KalVista's strategy to manage and influence its ownership structure.

Ownership Trends

Institutional ownership remained stable at 102.54% as of May 2025. Insider holdings saw a slight increase. The number of institutions reporting positions in KalVista increased in the last quarter of 2024, indicating continued interest.

Future Outlook

The anticipated FDA approval of sebetralstat is a key catalyst for KalVista stock. Analysts' positive outlook, with a potential upside of 102.02% as of June 13, 2025, could attract further investment. The company's strategic review of its preclinical program also signals future opportunities.

KalVista Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs